Stifel Nicolaus began coverage on shares of TRex Bio (NASDAQ:TRXB – Free Report) in a research report report published on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $39.00 price target on the stock.
Several other research firms have also weighed in on TRXB. JPMorgan Chase & Co. initiated coverage on shares of TRex Bio in a research note on Tuesday. They set an “overweight” rating and a $20.00 price objective on the stock. Wedbush began coverage on shares of TRex Bio in a report on Monday. They set an “outperform” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $29.67.
Get Our Latest Stock Report on TRex Bio
TRex Bio Price Performance
Shares of TRXB stock opened at $12.99 on Tuesday. TRex Bio has a one year low of $12.50 and a one year high of $16.56.
Insider Buying and Selling at TRex Bio
In related news, major shareholder Alexandria Venture Investments acquired 178,571 shares of the stock in a transaction dated Tuesday, October 13th. The stock was bought at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the transaction, the insider directly owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
TRex Bio Company Profile
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
Read More
- Five stocks we like better than TRex Bio
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.
